Latest News

A US biotechnology-based pharmaceutical company focused on the development and commercialization of novel cancer therapies has appointed Aagami to seek companies in South Korea who would like to in-license their novel therapeuic vaccine platform.

Read more...

Aagami CEO Dinesh Jain will visit Seoul in South Korea in December 2016, to attend the Korea Drug Development Fund Techfair 2016. He is a key speaker for the event.  He will also be meeting several Bio Pharma companies to promote strategic partnerships for Aagami's clients who are developing new assets and technologies.

Read more...

A Canada based past client of Aagami, has appointed Aagami for seeking licensing/do-development partnerships for their Phase 3 chemotherapy candidate, in South Korea, Taiwan, Turkey, Austalia and New Zealand.

Read more...

Linda edited 2It gives us immense pleasure to announce that Linda Pullan has joined Aagami Inc. as a partner Consultant. We see it as a major development which will bring added value to our clients while also widen our reach.

Based in Southern California, Linda has a Ph.D., and over 25 years of pharmaceutical and biotech experience in research and licensing, business development, R&D and consulting.

Read more...

India's fast-growing BioEconomy has crossed the $35.1 billion in 2015, according to a Special Report prepared by the Association of Biotechnology-Led Enterprises(ABLE) and released on the inaugural day of the BIO International Conference at Moscone Convention Center in San Francisco on June 7. India has set an ambitious target of achieving a BioEconomy of $ 100 billion by the year 2025.

Read more...

Aagami CEO Dinesh Jain, and President Shubhra Jain are participating in the 2016 BIO International Convention which will be held next week (6-9) in San Francisco.
This Annual event is the world’s largest biotechnology gathering.

Read more...

After organising a conference at Illinois Science and Technology Park on June 2, Aagami CEO attended the French/American Partnering Day – Oncology, which was held on 03 June in Chicago. This event gathered French and American biotech companies specialized in oncology. 

Read more...

Aagami Inc. and Rosen Biosciences is organising an event on 02 June at the Illinois Science + Technology Park, Skokie, Illionois. This event will provide an overview of the Indian Pharma and Biotech Market, one of the largest and fastest-growing in the world.

Read more...

Bringing success to its clients is the prime focus of Aagami and it has brought another success to its Australian biotechnology client, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY).

On 18 May, POH announced that it has expanded its existing agreement with Themis Medicare Limited, India, for its TPM®/Diclofenac gel, to include an additional 16 geographical markets.

Phosphagenics was advised on this licensing transaction by Aagami.

This is the 4th strategic partnership that Aagami has facilitated for POH, and looks forward to cementing further partnerships soon.

Aagami has signed up with another new client in the US. Client has a unique technology to delivery technology, which bypasses the Blood Brain Barrier (BBB) enabling drugs to reach the brain, hence enabling next-generation therapeutics for CNS disorders.

Read more...

Aagami CEO and Head – BD brought their Australian client CEO and VP in the holy week of March to India for high level and strategic meetings with Indian Pharma companies with whom advanced level discussions were in progress.

Read more...

A New York based plant biotech company has appointed Aagami to find licensing partners for their IP protected smoking cessation aid products.The client is poised to disrupt and penetrate the stale multi-billion dollar smoking cessation market with genetic engineering of the tobacco plant to decrease nicotine and other nicotinic alkaloids.

Read more...